Additional Broadridge resources:
View our Contact Us page for additional information.
One of our sales representatives will email you about your submission.
Welcome back, {firstName lastName}.
Not {firstName}? Clear the form.
Want to speak with a sales representative?
Your sales rep submission has been received. One of our sales representatives will contact you soon.
Our representatives and specialists are ready with the solutions you need to advance your business.
Want to speak with a sales representative?
Table Heading | |
---|---|
+1 800 353 0103 | North America |
+442075513000 | EMEA |
+65 6438 1144 | APAC |
Your sales rep submission has been received. One of our sales representatives will contact you soon.
Want to speak with a sales representative?
Table Heading | |
---|---|
+1 800 353 0103 | North America |
+442075513000 | EMEA |
+65 6438 1144 | APAC |
Nos représentants et nos spécialistes sont prêts à vous apporter les solutions dont vous avez besoin pour faire progresser votre entreprise.
Vous voulez parler à un représentant commercial?
Table Heading | |
---|---|
+1 800 353 0103 | Amérique du Nord |
+1 905 470 2000 | Canada Markham |
+1 416 350 0999 | Canada Toronto |
Votre soumission a été reçue. Nous communiquerons avec vous sous peu.
Vous souhaitez parler à un commercial ?
Table Heading | |
---|---|
+1 800 353 0103 | Amérique du Nord |
+1 905 470 2000 | Canada Markham |
+1 416 350 0999 | Canada Toronto |
The financial crisis in 2008 and the collapse of Lehman Brothers sent shock waves through the financial industry, creating a ripple effect which eventually engulfed the entire financial world. It was evident and inevitable that more robust regulations were required to ensure the stability and good health of financial markets. The G20 economies sought help from Basel Committee on Banking Supervision (BCBS) International Organisation of Securities Commissions (IOSCO) to regulate Over-the-Counter (OTC) derivatives industry. Amongst various other initiatives, Uncleared Margin Rules (UMR) were developed by BCBS IOSCO to regulate non-cleared derivative transactions. The aim was to implement stringent measures for the participants in the OTC derivatives market. If one was to pose the question to market participants, “Are you finding it increasingly challenging difficult to trade derivatives”, the answer has been an emphatic ‘Yes’.
However, sophisticated OTC collateral management platforms and the phased approach of the UMR regulation has enabled market participants to adapt gradually to the requirements and comply with relative ease. The collateral management teams across derivatives markets have been busy since mid-late 2015 to early 2016 in assessing the requirements, determining which phase their firm will be captured, ensuring operational readiness by allocating substantial resources (time, money; effort) with an aim to seamlessly deliver a solution to comply with regulation.
The checklist of most project teams for UMR across the industry looked something like the below,
New agreements in scope (based on AANA) | ✓ |
Set up of agreements in Collateral Systems | ✓ |
Conversation with counterparties about the scope | ✓ |
Discuss best practices with counterparties | ✓ |
Availability of HQLA based on eligibility | ✓ |
Operational set ups etc. | ✓ |
Most of the resources available were directed towards the aspects mentioned in the above table. However, one key component that the majority of industry participants did not allocate adequate importance and resources to, was the timely settlement of collateral. Considering that the main goal of collateral management is to ensure that counterparty default risk is mitigated, settlement of the agreed collateral should be the most fundamental task of any collateral management department. Over the years collateral settlement fails have been considered an operational nuisance and have suffered from a ‘laissez faire’ attitude.
Historically, a typical day in a collateral management department looked like below,
The fact that checking collateral settlement fails was, and to some extent is still, at the bottom of this list is quite concerning. Over the years, industry participants have discussed and debated how best to ensure appropriate regulations are applied to the derivatives industry, however, not much attention has been paid to ensure that the collateral exchanged between two parties has settled in the market.
Industry participants generally exchange both cash and non-cash (mostly bonds) collateral to cover exposure for an OTC derivative agreement. Most buy side firms are risk averse and do not exercise their right to rehypothecate keeping the received collateral ringfenced, so one would expect a robust fails remediation process. These firms generally manage derivatives exposure on behalf of their clients and an increase in collateral fails amounts to failure in risk management services. The sell-side firms have been more welcoming to the idea of rehypothecation and manage their inventory as per in-house optimization processes. A cash collateral fail for a sell-side firm means uncollateralized exposure, which is of grave concern on its own. However, a non-cash collateral fail not only means uncollateralized exposure but also, most likely, breaking the chain of collateral exchange. For instance, if the rehypothecated collateral is not received back in time, the option for the party involved is to either use securities from its own inventory or in a worst-case scenario borrow it from the market. In either of the cases, there is additional cost to the trading books along with the already existing operational costs.
The introduction of UMR regulations and development of sophisticated OTC collateral management systems have moved in conjunction with each other for the past 5-6 years. The new and sophisticated OTC Collateral Management systems have ensured that the core margin call activities (issuing/agreeing margin calls) are a lot less time consuming compared to 5-10 years ago. For example, most industry participants use TriResolve for reconciliations of OTC derivatives trades making the whole dispute resolution process quite seamless.
However, as an industry there has not been sufficient effort to effectively address the issue of collateral fails. Ideally, there should be a zero-tolerance policy towards collateral settlement fails but with the increase in margin call volumes under the UMR regime, some organizations have had to direct resources towards recruitment, driving the operational costs up, and away from appropriately and decisively addressing collateral fails.
The International Swaps and Derivatives Association (ISDA) margin survey reports the below numbers for each year from 2017 to 2021. If one was to assume that on an average 5% of collateral exchanged results into fails, the implications and the cost of uncollateralized exposure in the derivatives industry is worth taking note of.
Data in USD billions | |||||
---|---|---|---|---|---|
Margin and Collateral Fails | 2017 | 2018 | 2019 | 2020 | 2021 |
Initial Margin Exchanged | 130.60 | 162.70 | 183.70 | 217.80 | 304.10 |
Variation Margin Exchanged | 1,525.40 | 1442.50 | 944.70 | 1300.00 | 1000.00 |
Initial Margin Collateral Fails(5%) | 6.53 | 8.14 | 9.19 | 10.89 | 15.21 |
Variation Margin Collateral Fails(5%) | 76.27 | 72.13 | 47.24 | 65.00 | 50.00 |
It is quite evident that even after taking a conservative approach of 5% for collateral fails, the uncollateralized exposure & the associated operational cost to industry participants is enormous. A detailed empirical analysis performed by PwC & DTCC prior to the start of UMR phase -1 estimated this to be around 10% by the time phases 5 & 6 were implemented.
The question that regulators, government institutions, customers of industry participants and the industry participants need to ask themselves is, what does UMR compliance mean and what does “fully collateralized” mean? Does it merely mean that a financial institution is processing margin variation and initial margin calls daily or does it mean being fully cognizant about how much of margin (IM & VM) exchanged has settled on the agreed value date?
There is a fair degree of consensus among industry participants that collateral settlement fails in an organization could be due to fundamental issues such as lack of infrastructure, limited resources, increase in volumes of margin calls, etc. However, on the majority of occasions, collateral fails are a result of suboptimal processes for effective collateral settlement monitoring.
It is safe to infer that collateral settlement fails increase costs for an organization, disturb market stability, could cause reputational damage and in the worst of all the cases raises questions on effective management of counterparty risk. Even though BCBS & IOSCO have implemented UMR and have ensured that the majority of firms trading derivatives adhere to it, it is the responsibility of each individual organization to ensure that they are fully compliant and genuinely fully collateralized.
It is imperative that a change in attitude is required from the industry participants towards collateral settlement process and the first step is to have a proactive approach in ensuring that all collateral is settled on a timely manner. A platform that fully incorporates & integrates all aspects of collateral management along with performing post trade activities is another important step that will help firms in reducing collateral fails. Broadridge is heavily investing in providing such a solution for both cleared and non-cleared derivatives collateral management. Broadridge’s SFCM Collateral Management Module and the associated Asset Selection Module (ASM) has real time connectivity to electronic messaging services like Acadia, reconciliation platforms like TriResolve and all major custodians. An ‘everything under one roof’ solution can help a collateral management team in ticking all the boxes, becoming more efficient and achieving full & real compliance with the regulation.
Our representatives and specialists are ready with the solutions you need to advance your business.
Want to speak with a sales representative?
Table Heading | |
---|---|
+1 800 353 0103 | North America |
+442075513000 | EMEA |
+65 6438 1144 | APAC |
Your sales rep submission has been received. One of our sales representatives will contact you soon.
Want to speak with a sales representative?
Table Heading | |
---|---|
+1 800 353 0103 | North America |
+442075513000 | EMEA |
+65 6438 1144 | APAC |